Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.
about
Efficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity.Can we unlock the potential of IGF-1R inhibition in cancer therapy?Association of polymorphisms and haplotypes in the insulin-like growth factor 1 receptor (IGF1R) gene with the risk of breast cancer in Korean women.Differential expression of the insulin-like growth factor receptor among early breast cancer subtypes.Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage DifferentiationThe Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link.Primary breast cancer cell culture yields intra-tumor heterogeneous subpopulations expressing exclusive patterns of receptor tyrosine kinases.Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer.HER2-family signalling mechanisms, clinical implications and targeting in breast cancer.IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831.Involvement of microRNAs in HER2 signaling and trastuzumab treatment.Downregulation of miR-383 promotes glioma cell invasion by targeting insulin-like growth factor 1 receptor.Phenformin inhibits growth and epithelial-mesenchymal transition of ErbB2-overexpressing breast cancer cells through targeting the IGF1R pathwayCo-targeting the HER and IGF/insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease.EGFR-TKIs resistance via EGFR-independent signaling pathways.Revisiting the IGF-1R as a breast cancer target.
P2860
Q30313117-FCD20C95-FEF9-4633-AB7F-7D1A9C1447FCQ34336988-54D23A35-9D10-4106-A331-1086916DCEC7Q35083425-B78340AA-DBEC-4FD8-BF70-E866DEEA59E2Q35123145-009ED3EA-1B9B-4E4D-890A-14789ACDFD1FQ35535296-E26C3F3D-0B4D-4CEB-A4E9-65DC4A2C3B4CQ35609517-1C27AA25-9248-4514-9EA8-96B91348494AQ36137401-21276A1A-9A36-4A24-AE9A-4C24F98667BBQ36782629-78D761D5-57C6-49EA-A2A6-385362C7B2F2Q38301236-D2A795A0-709C-4477-893B-944E0F44363DQ38770018-4F1CB7A7-7534-4D0C-90D1-E12C2FAC8877Q38979308-D35A3CD6-FC51-4948-BC37-A975DBCA9FF6Q39169837-9D35C5AE-8594-4BDC-9602-874A11B5CDC9Q41694168-E718AB46-2FC3-4224-BC63-27D1BCFCCBF5Q48195377-AF937DEC-FD1C-4521-8DAC-0F118F087A04Q49887890-98EC7037-30E4-443E-9704-C10FB68EEA0CQ52686152-E0C32AB0-B36D-426B-A5A3-4223817E6F0B
P2860
Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Evaluation of IGF1R and phosph ...... cancer cell lines and tumours.
@en
Evaluation of IGF1R and phosph ...... cancer cell lines and tumours.
@nl
type
label
Evaluation of IGF1R and phosph ...... cancer cell lines and tumours.
@en
Evaluation of IGF1R and phosph ...... cancer cell lines and tumours.
@nl
prefLabel
Evaluation of IGF1R and phosph ...... cancer cell lines and tumours.
@en
Evaluation of IGF1R and phosph ...... cancer cell lines and tumours.
@nl
P2093
P2860
P50
P1476
Evaluation of IGF1R and phosph ...... cancer cell lines and tumours.
@en
P2093
Annemarie Larkin
Brigid C Browne
Francesco Sclafani
John Crown
John Kennedy
Kasper Pedersen
Martina S J McDermott
Michael J Duffy
Neil A O'Brien
P2860
P2888
P304
P356
10.1007/S10549-012-2260-9
P407
P577
2012-11-02T00:00:00Z